HRP20171961T1 - Kemijski spojevi - Google Patents
Kemijski spojevi Download PDFInfo
- Publication number
- HRP20171961T1 HRP20171961T1 HRP20171961TT HRP20171961T HRP20171961T1 HR P20171961 T1 HRP20171961 T1 HR P20171961T1 HR P20171961T T HRP20171961T T HR P20171961TT HR P20171961 T HRP20171961 T HR P20171961T HR P20171961 T1 HRP20171961 T1 HR P20171961T1
- Authority
- HR
- Croatia
- Prior art keywords
- fluoro
- pyrido
- phenyl
- indol
- methylpropyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 19
- 150000003839 salts Chemical class 0.000 claims 12
- DFBDRVGWBHBJNR-BBNFHIFMSA-N (e)-3-[3,5-difluoro-4-[(1r,3r)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C1([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H](N2CC(C)(C)F)C)=C(F)C=C(\C=C\C(O)=O)C=C1F DFBDRVGWBHBJNR-BBNFHIFMSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- QZKOBFIEGIQDMU-MYSGNRETSA-N (E)-3-[3,5-difluoro-4-[(3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-3,4-dihydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C([C@H]([N+]=1CC(C)(C)F)C)c(c2c(cccc2)[nH]2)c2C=1c1c(F)cc(\C=C\C([O-])=O)cc1F QZKOBFIEGIQDMU-MYSGNRETSA-N 0.000 claims 1
- STVQFMFTCUMADM-XGMWYDOHSA-N (e)-3-[3,5-difluoro-4-[(1r,3r)-2-[(2s)-3-fluoro-2-methylpropyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C1([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H](C)N2C[C@@H](CF)C)=C(F)C=C(\C=C\C(O)=O)C=C1F STVQFMFTCUMADM-XGMWYDOHSA-N 0.000 claims 1
- AKZLESYLLLKGNZ-MDZDMXLPSA-N (e)-3-[3,5-difluoro-4-[2-(2-fluoro-2-methylpropyl)-3,3-dimethyl-4,9-dihydro-1h-pyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C1=2NC3=CC=CC=C3C=2CC(C)(C)N(CC(C)(F)C)C1C1=C(F)C=C(\C=C\C(O)=O)C=C1F AKZLESYLLLKGNZ-MDZDMXLPSA-N 0.000 claims 1
- XTDHJGCTXMSPCY-RSEBSXLISA-N (e)-3-[3,5-difluoro-4-[2-[(2s)-3-fluoro-2-methylpropyl]-3,3-dimethyl-4,9-dihydro-1h-pyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C1=2NC3=CC=CC=C3C=2CC(C)(C)N(C[C@@H](CF)C)C1C1=C(F)C=C(\C=C\C(O)=O)C=C1F XTDHJGCTXMSPCY-RSEBSXLISA-N 0.000 claims 1
- IOPRLAHXDGSIHG-NAUGMMEESA-N (e)-3-[3-fluoro-4-[2-[(2s)-3-fluoro-2-methylpropyl]-3,3-dimethyl-4,9-dihydro-1h-pyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C1=2NC3=CC=CC=C3C=2CC(C)(C)N(C[C@@H](CF)C)C1C1=CC=C(\C=C\C(O)=O)C=C1F IOPRLAHXDGSIHG-NAUGMMEESA-N 0.000 claims 1
- DFBDRVGWBHBJNR-NYKMLEKOSA-N (e)-3-[4-[(1r,3r)-1-deuterio-2-(2-fluoro-2-methylpropyl)-3-methyl-4,9-dihydro-3h-pyrido[3,4-b]indol-1-yl]-3,5-difluorophenyl]prop-2-enoic acid Chemical compound C1([C@@]2(C3=C(C4=CC=CC=C4N3)C[C@@H](C)N2CC(C)(C)F)[2H])=C(F)C=C(\C=C\C(O)=O)C=C1F DFBDRVGWBHBJNR-NYKMLEKOSA-N 0.000 claims 1
- HYPDMBONKGTBLC-NVEBTIFVSA-N (e)-3-[4-[(1r,3r)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C1([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H](N2CC(C)(C)F)C)=CC=C(\C=C\C(O)=O)C=C1 HYPDMBONKGTBLC-NVEBTIFVSA-N 0.000 claims 1
- CLDCRFJRMORRTI-IEGMAYJBSA-N (e)-3-[4-[(1r,3r)-2-[(2s)-3-fluoro-2-methylpropyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C1([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H](C)N2C[C@@H](CF)C)=CC=C(\C=C\C(O)=O)C=C1 CLDCRFJRMORRTI-IEGMAYJBSA-N 0.000 claims 1
- RZLKPYCEHAUODL-SDNWHVSQSA-N (e)-3-[4-[2-(2-fluoro-2-methylpropyl)-3,3-dimethyl-4,9-dihydro-1h-pyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C1=2NC3=CC=CC=C3C=2CC(C)(C)N(CC(C)(F)C)C1C1=CC=C(\C=C\C(O)=O)C=C1 RZLKPYCEHAUODL-SDNWHVSQSA-N 0.000 claims 1
- WRHLOSDZEZAYKX-WFSDQYTKSA-N (e)-3-[4-[2-[(2s)-3-fluoro-2-methylpropyl]-3,3-dimethyl-4,9-dihydro-1h-pyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C1=2NC3=CC=CC=C3C=2CC(C)(C)N(C[C@@H](CF)C)C1C1=CC=C(\C=C\C(O)=O)C=C1 WRHLOSDZEZAYKX-WFSDQYTKSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Claims (16)
1. Spoj s formulom (I)
[image]
naznačen time da:
R1 i R2 su svaki neovisno H ili F;
R3 je H ili metil; i
bilo koji od:
a) R4 je H i R5 je F; ili
b) R4 je F i R5 je H;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da spoj je spoj s formulom (IA).
[image]
3. Spoj prema zahtjevu 1 ili zahtjevu 2, ili farmaceutski prihvatljiva sol naznačen time da R3 je vodik.
4. Spoj prema bilo kojem od prethodnih zahtjeva, ili njegova farmaceutski prihvatljiva sol naznačen time da R4 je vodik i R5 je fluoro.
5. Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol naznačen time da je spoj odabran od:
(E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline;
(E)-3-(4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline;
(E)-3-(3,5-difluoro-4-((1R,3R)-2-((S)-3-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline;
(E)-3-(4-((1R,3R)-2-((S)-3-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline;
(E)-3-(3,5-difluoro-4-(2-((S)-3-fluoro-2-metilpropil)-3,3-dimetil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline;
(E)-3-(3,5-difluoro-4-(2-(2-fluoro-2-metilpropil)-3,3-dimetil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline;
(E)-3-(4-(2-((S)-3-fluoro-2-metilpropil)-3,3-dimetil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline;
(E)-3-(4-(2-(2-fluoro-2-metilpropil)-3,3-dimetil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline;
(E)-3-(3-fluoro-4-(2-((S)-3-fluoro-2-metilpropil)-3,3-dimetil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline; i
(E)-3-[4-[(1R,3R)-1-deuterio-2-(2-fluoro-2-metil-propil)-3-metil-4,9-dihidro-3H-pirido[3,4-b]indol-1-il]-3,5-difluoro-fenil]prop-2-enske kiseline.
6. Spoj prema zahtjevu 5, naznačen time da je (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline, koji spoj ima slijedeću strukturu:
[image]
ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema zahtjevu 6 naznačen time da je (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline.
8. Spoj prema zahtjevu 6 naznačen time da je maleatna sol (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline.
9. Spoj prema zahtjevu 7 u kristalnom obliku, naznačen time da ima uzorak difrakcije X-zraka na prahu (XRPD) s barem dva specifična maksimuma 2-theta = 8.4° i 10.9° pri čemu navedene vrijednosti mogu biti plus ili minus 0.2° 2-theta.
10. Spoj prema bilo kojem od prethodnih zahtjeva, ili njegova farmaceutski prihvatljiva sol naznačen time da je uporabu kao lijek.
11. Spoj prema bilo kojem od zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol naznačen time da je uporabu za sprječavanje ili liječenje raka kod toplokrvne životinje kao što je čovjek.
12. Spoj za uporabu za sprječavanje ili liječenje raka, prema zahtjevu 11, naznačen time da je (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilna kiselina, ili njegova farmaceutski prihvatljiva sol.
13. Spoj za uporabu za liječenje raka, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 11 ili zahtjevu 12, naznačen time da rak je rak dojke ili ginekološki karcinom.
14. Farmaceutski pripravak naznačen time da sadrži spoj s Formulom (I) ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 9, te farmaceutski prihvatljivo sredstvo za otapanje ili nosač.
15. Farmaceutski pripravak prema zahtjevu 14 naznačen time da sadrži (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline ili njegova farmaceutski prihvatljiva sol, u kombinaciji s barem jednim farmaceutski prihvatljivim sredstvom za otapanje ili nosačem, pri čemu pripravak sadrži manje od 5% m/m (R,E)-3-(3,5-difluoro-4-(2-(2-fluoro-2-metilpropil)-3-metil-4,9-dihidro-3H-pirido[3,4-b]indol-2-ium-1-il)fenil)akrilata.
16. Farmaceutski pripravak prema zahtjevu 15, naznačen time da pripravak dodatno sadrži antioksidans i proizvoljno dodatno sadrži sredstvo za keliranje metala.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361827951P | 2013-05-28 | 2013-05-28 | |
US201361915685P | 2013-12-13 | 2013-12-13 | |
PCT/GB2014/051607 WO2014191726A1 (en) | 2013-05-28 | 2014-05-27 | Chemical compounds |
EP14727036.7A EP3004090B1 (en) | 2013-05-28 | 2014-05-27 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171961T1 true HRP20171961T1 (hr) | 2018-02-09 |
Family
ID=50841880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171961TT HRP20171961T1 (hr) | 2013-05-28 | 2017-12-18 | Kemijski spojevi |
Country Status (35)
Country | Link |
---|---|
US (4) | US9155727B2 (hr) |
EP (2) | EP3360875A1 (hr) |
JP (1) | JP6286031B2 (hr) |
KR (1) | KR20160013198A (hr) |
CN (1) | CN105229004B (hr) |
AP (1) | AP2015008858A0 (hr) |
AU (1) | AU2014272856B2 (hr) |
BR (1) | BR112015029455A8 (hr) |
CA (1) | CA2911859A1 (hr) |
CL (1) | CL2015003491A1 (hr) |
CR (1) | CR20150629A (hr) |
CY (1) | CY1120474T1 (hr) |
DK (1) | DK3004090T3 (hr) |
DO (1) | DOP2015000274A (hr) |
ES (1) | ES2654161T3 (hr) |
HK (1) | HK1222859A1 (hr) |
HR (1) | HRP20171961T1 (hr) |
HU (1) | HUE035738T2 (hr) |
IL (1) | IL242559B (hr) |
LT (1) | LT3004090T (hr) |
ME (1) | ME02892B (hr) |
MX (1) | MX361538B (hr) |
NI (1) | NI201500167A (hr) |
PE (1) | PE20160874A1 (hr) |
PH (1) | PH12015502615A1 (hr) |
PL (1) | PL3004090T3 (hr) |
PT (1) | PT3004090T (hr) |
RS (1) | RS56678B1 (hr) |
RU (1) | RU2664109C2 (hr) |
SG (1) | SG11201509393VA (hr) |
SI (1) | SI3004090T1 (hr) |
TN (1) | TN2015000516A1 (hr) |
TW (1) | TWI653235B (hr) |
UY (1) | UY35590A (hr) |
WO (1) | WO2014191726A1 (hr) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2857344C (en) | 2011-12-21 | 2019-02-12 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
JP6505013B2 (ja) | 2012-08-28 | 2019-04-24 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 |
AU2014222641B2 (en) | 2013-02-28 | 2018-03-15 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B |
JP6419155B2 (ja) | 2013-04-03 | 2018-11-07 | ヤンセン・サイエンシズ・アイルランド・ユーシー | N−フェニル−カルボキサミド誘導体およびb型肝炎を治療するための医薬品としてのその使用 |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
US10160743B2 (en) | 2013-05-17 | 2018-12-25 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
LT3024819T (lt) | 2013-07-25 | 2018-06-11 | Janssen Sciences Ireland Uc | Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui |
WO2015059212A1 (en) | 2013-10-23 | 2015-04-30 | Janssen R&D Ireland | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
MX2016009449A (es) | 2014-02-05 | 2016-10-13 | Novira Therapeutics Inc | Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb). |
EP3102572B1 (en) | 2014-02-06 | 2018-10-24 | Janssen Sciences Ireland UC | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
AU2015367509B2 (en) | 2014-12-18 | 2020-01-02 | F. Hoffmann-La Roche Ag | Tetrahydro-pyrido(3,4-b)indole estrogen receptor modulators and uses thereof |
WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法 |
EP3312184A4 (en) * | 2015-06-16 | 2019-02-27 | Jiangsu Hengrui Medicine Co., Ltd. | PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
AU2016301196B2 (en) | 2015-08-06 | 2022-09-08 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
AU2016330964B2 (en) | 2015-09-29 | 2021-04-01 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
BR122023020677A2 (pt) | 2015-10-01 | 2023-12-12 | Olema Pharmaceuticals, Inc. | Compostos de tetra-hidro-1h-pirido[3,4-b]indol, composições compreendendo os referidos compostos e usos dos mesmos |
KR102099159B1 (ko) * | 2015-11-12 | 2020-04-10 | 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 | 아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법 |
RU2747802C2 (ru) | 2015-12-09 | 2021-05-14 | Зе Боард Оф Трастис Оф Зе Юниверсити Оф Иллинойс | Бензотиофеновые селективные блокаторы эстрогеновых рецепторов |
WO2017107754A1 (zh) | 2015-12-22 | 2017-06-29 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物、其制备方法及其在医药上的应用 |
JP6905539B2 (ja) * | 2016-02-05 | 2021-07-21 | インベンティスバイオ リミテッド ライアビリティ カンパニー | 選択的エストロゲン受容体分解剤およびその使用 |
RU2738646C2 (ru) * | 2016-04-01 | 2020-12-15 | РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС | Модуляторы эстрогеновых рецепторов |
AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
TW201803870A (zh) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | 化學化合物 |
CA3022377A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Targeted measure of transcriptional activity related to hormone receptors |
CN109661393A (zh) * | 2016-05-08 | 2019-04-19 | 上海诚妙医药科技有限公司 | 帕布昔利布的新晶型及其制备方法及其用途 |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3454862A4 (en) | 2016-05-10 | 2020-02-12 | C4 Therapeutics, Inc. | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
WO2017216279A1 (en) * | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | Heteroaryl estrogen receptor modulators and uses thereof |
US20170362228A1 (en) | 2016-06-16 | 2017-12-21 | Genentech, Inc. | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
WO2018001232A1 (zh) * | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
RU2019102647A (ru) | 2016-07-01 | 2020-08-03 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
TW201815789A (zh) | 2016-07-25 | 2018-05-01 | 瑞典商阿斯特捷利康公司 | 化合物 |
CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
CN110139674B (zh) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
CA3040040A1 (en) | 2016-10-24 | 2018-05-03 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
AU2018205262A1 (en) | 2017-01-06 | 2019-07-11 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
WO2018130123A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的五环类化合物及其应用 |
PT3494116T (pt) * | 2017-01-30 | 2020-01-28 | Astrazeneca Ab | Moduladores de recetores de estrogénio |
WO2018148440A1 (en) | 2017-02-08 | 2018-08-16 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
AU2018217809A1 (en) | 2017-02-10 | 2019-08-22 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
CN108864080B (zh) * | 2017-05-09 | 2021-10-15 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的四环类化合物及其应用 |
CN110536888B (zh) * | 2017-06-20 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法 |
RU2019142591A (ru) | 2017-06-29 | 2021-07-29 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
TWI829655B (zh) | 2017-10-18 | 2024-01-21 | 瑞士商諾華公司 | 用於選擇性蛋白質降解的組合物及方法 |
EA038160B1 (ru) * | 2017-11-30 | 2021-07-15 | Астразенека Аб | Модуляторы рецептора эстрогена |
CN109867659A (zh) * | 2017-12-04 | 2019-06-11 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物的制备方法 |
US10519152B2 (en) | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
WO2019162429A1 (en) * | 2018-02-23 | 2019-08-29 | Center For Intelligent Research In Crystal Engineering, S.L. | Cocrystals of ubiquinol and compositions comprising them |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
WO2019228443A1 (en) * | 2018-05-30 | 2019-12-05 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Selective estrogen receptor downregulators and uses thereof |
FI3810283T3 (fi) | 2018-06-21 | 2023-08-11 | Hoffmann La Roche | 3-((1r,3r)-1-(2,6-difluori-4-((1-(3-fluoripropyyli)atsetidin-3-yyli)amino)fenyyli)-3-metyyli-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yyli)-2,2-difluoripropan-1-olin tartraattisuolan kiinteitä muotoja, niiden valmistusmenetelmä ja menetelmiä niiden käyttämiseksi syöpien hoidossa |
CR20210060A (es) | 2018-07-03 | 2021-04-08 | Univ Illinois | Activadores de la respuesta a proteínas desplegadas |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
KR20210107783A (ko) | 2018-12-24 | 2021-09-01 | 인벤티스바이오 컴퍼니 리미티드 | 선택적 에스트로겐 수용체 분해제의 신규 염 |
CN113454077A (zh) | 2019-02-22 | 2021-09-28 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
MX2021013594A (es) | 2019-05-06 | 2021-12-10 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. |
JP2022532342A (ja) * | 2019-05-14 | 2022-07-14 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
CA3148221A1 (en) | 2019-08-06 | 2021-02-11 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
AU2020380211A1 (en) * | 2019-11-04 | 2022-05-19 | Recurium Ip Holdings, Llc | Salts and forms of an estrogen receptor modulator |
TW202131930A (zh) | 2019-11-13 | 2021-09-01 | 美商諾維雪碧歐公司 | 抗癌核荷爾蒙受體標靶化合物 |
KR20220125272A (ko) | 2020-01-10 | 2022-09-14 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 트리사이클릭 테트라하이드로이소퀴놀린 유도체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도 |
WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
MX2023001572A (es) * | 2020-08-05 | 2023-05-08 | Aizant Drug Res Solutions Private Limited | Formas farmaceuticas sólidas de palbociclib. |
WO2022109395A2 (en) | 2020-11-23 | 2022-05-27 | Sanofi | Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer |
WO2022140744A1 (en) | 2020-12-23 | 2022-06-30 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
US11834458B2 (en) | 2021-03-23 | 2023-12-05 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
AU2022269568A1 (en) | 2021-05-03 | 2023-11-16 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
WO2023283329A1 (en) * | 2021-07-08 | 2023-01-12 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
AU2022307207A1 (en) | 2021-07-09 | 2024-02-15 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Salt types of tricyclic tetrahydro isoquinoline derivative |
WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
JP2000509373A (ja) | 1996-04-19 | 2000-07-25 | ノボ ノルディスク アクティーゼルスカブ | ホスホチロシン認識ユニットを有する分子のモジュレーター |
FR2778404B1 (fr) * | 1998-05-06 | 2000-06-30 | Hoechst Marion Roussel Inc | Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
HUP0201291A3 (en) | 1999-04-28 | 2002-11-28 | Sanofi Aventis Deutschland | Di-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them |
FR2796644B1 (fr) * | 1999-07-23 | 2001-09-07 | Adir | Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
RU2277095C2 (ru) * | 2000-03-15 | 2006-05-27 | Санофи-Авентис Дойчланд Гмбх | Замещенные бета-карболины |
US6720331B2 (en) | 2001-04-03 | 2004-04-13 | National Sun Yat-Sen University | 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents |
AU2003205630A1 (en) | 2002-01-18 | 2003-07-30 | The Genetics Company Inc. | Beta-secretase inhibitors |
AU2003231032B2 (en) | 2002-04-22 | 2008-07-10 | Johns Hopkins University School Of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
US20050004164A1 (en) | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
ES2427166T3 (es) | 2003-06-23 | 2013-10-29 | Ono Pharmaceutical Co., Ltd. | Compuesto heterocíclico tricíclico novedoso |
KR20060066070A (ko) * | 2003-07-28 | 2006-06-15 | 스미스클라인 비참 코포레이션 | 에스트로겐 수용체의 조절제로서의 시클로알킬리덴 화합물 |
DE10335725A1 (de) | 2003-08-05 | 2005-03-03 | Bayer Cropscience Gmbh | Safener auf Basis aromatisch-aliphatischer Carbonsäuredarivate |
CN1910183A (zh) * | 2004-01-23 | 2007-02-07 | 希龙公司 | 四氢咔啉化合物作为抗癌药 |
PT1725553E (pt) * | 2004-03-11 | 2008-07-16 | Actelion Pharmaceuticals Ltd | Derivados de tetra-hidropiridoindole |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
US20060094747A1 (en) | 2004-10-28 | 2006-05-04 | The Institute For Pharmaceutical Discovery, L.L.C. | Substituted carboxylic acids |
AU2005307818A1 (en) | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocyclylbiphenyl derivates as protein Tyrosine phosphatase inhibitors |
CA2596015A1 (en) | 2005-02-14 | 2006-08-24 | Sampath K. Anandan | Fused heterocyclic compounds useful as inhibitors of histone deacetylase |
CN101175754A (zh) * | 2005-03-22 | 2008-05-07 | 阿斯利康(瑞典)有限公司 | 用作CB1受体配体的新四氢-1H-吡啶并[4,3-b]吲哚衍生物 |
US20070032385A1 (en) | 2005-06-20 | 2007-02-08 | Dunetz Joshua R | Sustainable chemical processes |
CN101489544A (zh) | 2006-05-09 | 2009-07-22 | 海玛奎斯特医药公司 | 治疗血液病的方法 |
DK2057156T3 (en) | 2006-08-23 | 2017-05-08 | Kudos Pharm Ltd | 2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS |
EP2054504A2 (en) | 2006-08-29 | 2009-05-06 | Reinnervate Limited | Retinoid compounds and their use |
WO2008124838A1 (en) | 2007-04-10 | 2008-10-16 | University Of Maryland, Baltimore | Compounds that inhibit human dna ligases and methods of treating cancer |
WO2008124836A2 (en) | 2007-04-10 | 2008-10-16 | Uwm Research Foundation, Inc. | Methods of reducing virulence in bacteria |
CA2683444A1 (en) | 2007-04-13 | 2008-10-23 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
JP2010533712A (ja) | 2007-07-19 | 2010-10-28 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗糖尿病化合物としてのベータカルボリン誘導体 |
US8198292B2 (en) * | 2008-07-03 | 2012-06-12 | Osteogenex, Inc. | Vinpocetine and eburnamonine derivatives for promoting bone growth, treating renal damage and cancer, and devices thereof |
TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
WO2010107485A1 (en) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
US20120202801A1 (en) | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
CA2999345A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
WO2012112965A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
WO2013022740A2 (en) | 2011-08-05 | 2013-02-14 | Corning Incorporated | Gpr35 ligands and the uses thereof |
-
2014
- 2014-05-27 EP EP17196495.0A patent/EP3360875A1/en not_active Withdrawn
- 2014-05-27 RS RS20171304A patent/RS56678B1/sr unknown
- 2014-05-27 SI SI201430531T patent/SI3004090T1/en unknown
- 2014-05-27 KR KR1020157036820A patent/KR20160013198A/ko not_active Application Discontinuation
- 2014-05-27 DK DK14727036.7T patent/DK3004090T3/en active
- 2014-05-27 ME MEP-2017-292A patent/ME02892B/me unknown
- 2014-05-27 PT PT147270367T patent/PT3004090T/pt unknown
- 2014-05-27 SG SG11201509393VA patent/SG11201509393VA/en unknown
- 2014-05-27 PE PE2015002429A patent/PE20160874A1/es active IP Right Grant
- 2014-05-27 JP JP2016516235A patent/JP6286031B2/ja not_active Expired - Fee Related
- 2014-05-27 AU AU2014272856A patent/AU2014272856B2/en not_active Ceased
- 2014-05-27 WO PCT/GB2014/051607 patent/WO2014191726A1/en active Application Filing
- 2014-05-27 BR BR112015029455A patent/BR112015029455A8/pt not_active Application Discontinuation
- 2014-05-27 EP EP14727036.7A patent/EP3004090B1/en active Active
- 2014-05-27 CN CN201480028785.1A patent/CN105229004B/zh not_active Expired - Fee Related
- 2014-05-27 HU HUE14727036A patent/HUE035738T2/en unknown
- 2014-05-27 AP AP2015008858A patent/AP2015008858A0/xx unknown
- 2014-05-27 CA CA2911859A patent/CA2911859A1/en not_active Abandoned
- 2014-05-27 ES ES14727036.7T patent/ES2654161T3/es active Active
- 2014-05-27 LT LTEP14727036.7T patent/LT3004090T/lt unknown
- 2014-05-27 PL PL14727036T patent/PL3004090T3/pl unknown
- 2014-05-27 US US14/287,332 patent/US9155727B2/en not_active Expired - Fee Related
- 2014-05-27 RU RU2015151502A patent/RU2664109C2/ru active
- 2014-05-27 TW TW103118498A patent/TWI653235B/zh not_active IP Right Cessation
- 2014-05-27 TN TN2015000516A patent/TN2015000516A1/en unknown
- 2014-05-27 MX MX2015016428A patent/MX361538B/es active IP Right Grant
- 2014-05-27 UY UY0001035590A patent/UY35590A/es not_active Application Discontinuation
-
2015
- 2015-08-31 US US14/840,342 patent/US9616050B2/en active Active
- 2015-11-11 DO DO2015000274A patent/DOP2015000274A/es unknown
- 2015-11-12 IL IL242559A patent/IL242559B/en not_active IP Right Cessation
- 2015-11-24 PH PH12015502615A patent/PH12015502615A1/en unknown
- 2015-11-27 CL CL2015003491A patent/CL2015003491A1/es unknown
- 2015-11-27 NI NI201500167A patent/NI201500167A/es unknown
- 2015-11-30 CR CR20150629A patent/CR20150629A/es unknown
-
2016
- 2016-09-22 HK HK16111116.8A patent/HK1222859A1/zh not_active IP Right Cessation
-
2017
- 2017-02-28 US US15/445,000 patent/US10130617B2/en not_active Expired - Fee Related
- 2017-12-18 HR HRP20171961TT patent/HRP20171961T1/hr unknown
-
2018
- 2018-01-03 CY CY20181100009T patent/CY1120474T1/el unknown
- 2018-10-12 US US16/158,527 patent/US20190038607A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171961T1 (hr) | Kemijski spojevi | |
JP2016522835A5 (hr) | ||
HRP20171028T1 (hr) | Indolski i indazolski spojevi koji aktiviraju ampk | |
HRP20171696T1 (hr) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
HRP20201043T1 (hr) | Spojevi 4-amino-imidazokinolina | |
HRP20210255T1 (hr) | Postupak priprave derivata karbamoilpiridona i međuprodukata | |
JP2015078230A5 (hr) | ||
MY173946A (en) | (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl) azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrazino[2,1-c] [1,2,4]triazine-1-carboxamide compound | |
MD4490C1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
JP2013032389A5 (hr) | ||
NZ716840A (en) | Combination formulation of two antiviral compounds | |
MX354482B (es) | Proceso de elaboración para derivados de pirimidina. | |
MD20140073A2 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
JP2011105738A5 (hr) | ||
JP2011518833A5 (hr) | ||
PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
MX2016008665A (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
JP2016518317A5 (hr) | ||
SG11201709593VA (en) | CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND | |
WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
JP2016532632A5 (hr) | ||
WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
HRP20161691T1 (hr) | Derivati ariletinila | |
SI3083605T1 (en) | COMPOUNDS OF FLUOROFENYL PIRAZOLE |